Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

New study underway at the Montreal Collaborative Center!

#TripleGivingTuesday Research Feature

New OMF funded study: Deep proteome and metabolome profiling

From the desk of Alain Moreau, PhD
Director of the ME/CFS Collaborative Research Center
at CHU Sainte-Justine/Université de Montréal

During this first week of #TripleGivingTuesday, I am honored to share the exciting news that a new study is underway at the ME/CFS Collaborative Research Center at the Université de Montréal!

Study name: Deep proteome and metabolome profiling
Study duration: 18 months

You might remember that researchers from my team at the OMF established Montreal CRC recently uncovered and validated 11 different microRNAs associated with ME/CFS that can differentiate ME/CFS patients from healthy patients — with 90 percent accuracy. Moreover, this finding may predict the therapeutic response ME/CFS patients have toward specific treatments. 

This new, OMF funded study will build on this finding by examining the plasma samples of 200 severely affected ME/CFS patients compared to 80 age- and sex- matched healthy controls. The plasma samples for each participant will be analyzed before and after applying a stress-test inducing a post-exertional malaise (PEM). 

The post-exertional stress challenge used in this study is an innovative method, allowing each participant to act as their own experimental control, by observing response to a standardized stress test. In other words, rather than comparing people with ME to others, who may have a very different symptom profile, we measure their unique responses, pre and post stress testing, in circulating miRNA profiles (or any other biomarkers). 

This method is more likely to reveal disease-specific markers and reduce the influence of other factors like current medication, illness duration, age, sex and even the presence of certain comorbidities. Secondly, our method is portable, and cost-effective. It can allow the testing of individuals severely affected (e.g., housebound) who rarely participate in clinical studies. 

This study will examine the same plasma samples using multiple technologies, in partnership with OMF Collaborative ME/CFS Research Centers at Melbourne, Uppsala  and Montreal. Ultimately, this initiative aims to reveal disease-specific markers, better understand the molecular mechanisms underlying ME/CFS pathophysiology and discover treatment and intervention strategies.  

I am very encouraged by the potential opportunity this study has to change the lives of people with ME/CFS around the globe! Please join OMF on our mission to end the suffering experienced by millions. When you donate today, you help ensure that our team has the resources necessary to fulfill this project’s promise — along with many others — to advance the clinical care of people with multisystem chronic, complex diseases.

There’s no better time to give — Your gift of any amount made any day from now until November 30, 2021, will be TRIPLED, giving you the exciting opportunity to accelerate these critical research project

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo